017180.KS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 09:30):

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally...

Stats
Šios dienos apimtis	23 309.00
Vidutinė apimtis	66 342.00
Rinkos kapitalizacija	69.40B
EPS	KRW0 ( 2023-11-14 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW2.65 (0.13%)

Tūris Koreliacija

Ilgas: 0.11 (neutral)

Trumpas: 1.00 (very strong)

Signal:(58.929) Expect same movement, but be aware

MYUNGMOON Pharm co.,Ltd Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

MYUNGMOON Pharm co.,Ltd Koreliacija - Valiuta/Žaliavos

-0.15
( neutral )

0.61
( weak )

-0.36
( neutral )

-0.70
( moderate negative )

0.08
( neutral )

0.52
( weak )

MYUNGMOON Pharm co.,Ltd Finansinės ataskaitos

Annual	2023
Pajamos:	KRW169.57B
Bruto pelnas:	KRW94.52B (55.74 %)
EPS:	KRW-134.35

FY	2023
Pajamos:	KRW169.57B
Bruto pelnas:	KRW94.52B (55.74 %)
EPS:	KRW-134.35

FY	2022
Pajamos:	KRW152.13B
Bruto pelnas:	KRW78.10B (51.34 %)
EPS:	KRW232.74

FY	2021
Pajamos:	KRW144.76B
Bruto pelnas:	KRW62.34B (43.06 %)
EPS:	KRW0

Financial Reports:

No articles found.

MYUNGMOON Pharm co.,Ltd

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, fillers, and anti-obesity agents for pharmacotherapy. The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, oral disease products, antidiarrheal agents, digestive system products, cold drugs, calcium products, nasal sprays, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products. In addition, it offers health supplements, quasi drugs, and blended juices. MYUNGMOON Pharm co.,Ltd was founded in 1983 and is headquartered in Seoul, South Korea.